Preview

Пульмонология

Расширенный поиск

Эффективность тиотропиума бромида по влиянию на параметры функции внешнего дыхания: данные клинических исследований

Полный текст:

Об авторе

З. Р. Айсанов
НИИ пульмонологии Минздрава РФ
Россия

Москва



Список литературы

1. American Thoracic Society. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease (COPD). Am. J. Respir. Crit. Care. Med. 1995; 152: S77-S120.

2. Barnes P.J., Belvisi M.G., Mak J.C.W. et al. Tiotropium bromide (Ba 679 Br), a novel long-acting muscarinic antagonist for the treatment of obstructive airways disease. Life Sei. 1995; 56: 853-859.

3. Barnes P.J. Novel approaches and targets for treatment of chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 1999; 160: S72-S79.

4. Barnes P.J. The pharmacological properties of tiotropium. Chest 2000; 117: S63-S66.

5. Calverley P.M. The future for tiotropium. Ibid. S67-S69.

6. Casaburi R., Briggs D.D.Jr., Donohue J.F. et al. The spirometric efficacy of once-daily dosing with tiotropium in stable COPD: a 13-week multicenter trial. Ibid. 118: 1294-1302.

7. Casaburi R., Mahler D.A., Jones P.W. et al. A long-term evaluation of once-daily inhaled tiotropium in chronic obstructive pulmonary disease. Eur. Respir. J. 2002; 19: 217-224.

8. Celli B., ZuWallack R.t Wang S., Keste S. Improvements in inspiratory capacity with tiotropium in patients with COPD. Ibid. (suppl.): 3079.

9. Disse B., Raichl R., Speck G.A. et al. BA679BR, a novel anticholinergic bronchodilator. Life Sci. 1993; 52: 537-544.

10. Disse B., Speck G.A., Rominger K.L. et al. Tiotropium (Spiriva): mechanistical considerations and clinical profile in obstructive lung disease. Ibid. 1999; 64: 457-464.

11. Donohue J.F., van Noord J.A., Bateman E.D. et al. A 6-month placebo-controlled study comparing lung function and health status changes in COPD patients treated with tiotropium or salmeterol. Chest 2002; 122: 47-55.

12. ERS Consensus Statement. Optimal assessment and management of chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1995; 8: 1398-1420.

13. Global initiative for chronic obstructive lung disease (GOLD). Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease (executive summary). Bethesda, MD: National Institutes of Health; 2001.

14. Gross N.J., Skorodin M.S. Role of the parasympathetic system in airway obstruction due to emphysema. N. Engl. J. Med. 1984; 311: 421-425.

15. Haddad E.B., Mak J.C.W., Barnes P.J. Characterization of [3H]Ba 679 BR, a slowly dissociating muscarinic antagonist, in human lung: radioligand binding and autoradiographic mapping. Mol. Pharmacol. 1994; 45: 899-907.

16. Joos G.F. Potential usefulness of inhibiting neural mechanisms in asthma. Monaldi Arch. Chest. Dis. 2000; 55: 411-414.

17. Karpel J.P. Bronchodilator responses to anticholinergic andadrenergic agents in acute and stable COPD. Chest 1991; 99: 871-876.

18. LeDoux E.J., Morris J.F., Temple W.P. et al. Standard and double dose ipratropium bromide and combined ipratropium bromide and inhaled metaproterenol in COPD. Ibid. 1989; 95: 1013-1016.

19. Lefkowitz R.J., Hoffman B.B., Taylor P. Neurohumoral transmission: the autonomic and somatic motor nervous systems. In: Gilman A.G. et al. eds. Goodman and Gilman's the pharmacological basis of therapeutics. 8th ed. Elmsford, NY: Pergamon Press, Inc.; 1990. 84-121.

20. Littner M.R., Ilowite J.S., Tashkin D.P. et al. Long-acting bronchodilation with once daily dosing of tiotropium (Spiriva) in stable chronic obstructive pulmonary disease. Am. J. Respir. Crit. Care Med. 2000; 161: 1136-1142.

21. Maesen F., Smeets J., Sledsens T. et al. Tiotropium bromide, a new long-acting antimuscarinic bronchodilator: a pharmacodynamic study in patients with chronic obstructive pulmonary disease (COPD). Eur. Respir. J. 1995; 8: 1506-1513.

22. O'Connor B.J., Towse L.J., Barnes P.J. Prolonged effect of tiotropium bromide on methacholine-induced bronchoconstriction in asthma. Am. J. Respir. Crit. Care Med. 1996; 154: 876-880.

23. O'Donnel D.E., Helgo M agnussen H., Gerken F. et al. Mechanisms of improved exercise tolerance in COPD in response to tiotropium. Eur. Respir. J. 2002; 19 (suppl.): 1826.

24. Standards for the diagnosis and care of patients with chronic obstructive pulmonary disease. ATS statement. Am J. Respir. Crit. Care Med. 1995; 152: S77-S120.

25. Van Noord J.A., Bantje Th.A., Eland M.E. et al. A randomised controlled comparison of tiotropium and ipratropium in the treatment of chronic obstructive pulmonary disease. Thorax 2000; 55: 289-294.

26. Vincken W., van Noord J.A., Greefhorst A.P.M. et al. Improved health outcomes in patients with COPD during 1 yr's treatment with tiotropium. Eur. Respir. J. 2002; 19: 209-216.


Для цитирования:


Айсанов З.Р. Эффективность тиотропиума бромида по влиянию на параметры функции внешнего дыхания: данные клинических исследований. Пульмонология. 2003;(5):105-110.

For citation:


Aisanov Z.R. A Influence of Spiriva on lung function parameters: clinical research data. PULMONOLOGIYA. 2003;(5):105-110. (In Russ.)

Просмотров: 9


ISSN 0869-0189 (Print)
ISSN 2541-9617 (Online)